Johnson & Johnson's COVID-19 Vaccine Proves Successful in South Africa

Johnson & Johnson's COVID-19 has had positive results in South Africa, the co-head of a trial, Glenda Gray, told reporters Friday.

A research study conducted from mid-February to May with upwards of 470,000 health workers showed positive results in those inoculated, and the country’s health regulator approved the single-shot J&J vaccine in Apri. It is being used in addition to Pfizer's. The study showed 91% to 96.2% protection against death, Gray said, and 67% efficacy against infection when the beta coronavirus dominated and 71% when the delta variant did. As of Thursday, more than 8.3 million people had been vaccinated in South Africa.